每经AI快讯，有投资者在投资者互动平台提问：请分析一下重庆精准生物最近新获批上市新药普利得 凯对本公司的影响？ 智飞生物（300122.SZ）11月14日在投资者互动平台表示，公司参股企业重庆智睿投资有限公司投资孵 化了重庆精准生物技术有限公司。近期，精准生物自主研发的国家1类生物新药普基奥仑赛注射液已获 批上市。相关情况请以该公司公开发布的信息为准。 （文章来源：每日经济新闻） ...

Core Insights - China's bio-economy is showing a positive trend, with significant advancements in CAR-T cell therapy, original drug production, and brain-machine interface medical devices, positioning the country as the second-largest biopharmaceutical market globally [1][2] Industry Overview - The global bio-manufacturing industry is receiving heightened attention from major economies, with increased funding for genetic and cell engineering research, biomass utilization, and bio-based product development [2] - The number of CAR-T clinical research centers worldwide has grown to 2069 in 2024, a 60% increase from 1297 in 2020, with China hosting 388 centers, ranking second globally [2] - China has achieved a record high in the proportion of self-developed new drugs, with 93 new drugs approved by the National Medical Products Administration in 2024, marking a five-year peak [2] Research and Development - In 2024, China published over 20,000 SCI papers in the medical equipment field, leading globally in research output [3] - The bio-economy in China is characterized by a robust industrial foundation, with significant growth in the pharmaceutical and chemical sectors driven by advancements in synthetic biology and high-throughput screening technologies [3] Industry Transformation - The bio-industry is transitioning from "quantitative accumulation" to "qualitative leap," focusing on core technology breakthroughs, product quality upgrades, and enhancing supply chain resilience [4] - Notable innovations include the approval of the world's first "rice-derived" human serum albumin injection and the launch of the world's first 5.0T whole-body MRI system [4] Future Prospects - Innovations in synthetic biology and gene editing are driving rapid growth in bio-manufacturing, outpacing GDP growth, and positioning the bio-economy as a crucial sector in the future global economy [5]

Group 1 - The 17th China Bioindustry Conference highlighted the theme "Biotechnology Empowering the Future, Biomanufacturing Reshaping the World," showcasing the latest achievements in China's biotechnology and biomanufacturing sectors [1] - Wuhan has developed a comprehensive biopharmaceutical industry cluster, with a scale exceeding 550 billion yuan, playing a significant role in both national and global biomanufacturing [1] - The "China Bioeconomy Development Report 2025" indicates that China ranks second globally in research centers and is a major player in the biopharmaceutical market, gradually participating in international competition [1][2] Group 2 - In 2024, China approved 93 new drugs, the highest in five years, and is now the second-largest biopharmaceutical market globally, with a growing number of research drugs [2] - China leads the world in medical device patent applications, with 91,513 applications, accounting for nearly 70% of the global total [2] - The Hubei Pathology Big Data Database is expected to exceed 5 million high-precision digital slices by the end of 2025, significantly enhancing medical institutions and driving innovation [2] Group 3 - China's bioeconomy is robust, with a steady growth trend, and the global bioeconomy is projected to grow from $40-50 trillion to $30 trillion by 2050, with a compound annual growth rate of 8.6% [3] - Advances in synthetic biology and high-throughput screening technologies have led to significant breakthroughs in the production of pharmaceutical chemicals using microbial cell factories [3] - In the field of agricultural biotechnology, China accounts for 23% of the global market share in biological breeding, which has effectively reduced production costs and pesticide usage [3]

Core Viewpoint - China's biomanufacturing and biotechnology sectors are experiencing significant growth, with advancements in CAR-T cell therapy, biopharmaceuticals, and digital pathology, positioning the country as a global leader in these fields [3][5][10]. Group 1: Biopharmaceuticals - China ranks second globally in the number of CAR-T clinical research centers, with 388 centers as of 2024, reflecting a 60% increase from 2020 [7]. - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with the number of new drug approvals reaching a five-year high of 93 in 2024 [6][7]. - China is now the second-largest biopharmaceutical market globally, with a significant number of drugs in development, narrowing the gap with the United States [7]. Group 2: Biotechnology and Innovation - The report highlights that China leads globally in biotechnology patent applications and research personnel, with over 30% of new innovative drugs and research pipelines originating from the country [5][11]. - The establishment of 23 biomanufacturing bases across the country indicates a robust infrastructure supporting the growth of the biomanufacturing sector [5]. - The "National Innovative Drug Insight System" was launched to enhance the efficiency of drug development and address challenges in identifying quality projects and matching strategic resources [9]. Group 3: Digital Pathology and Medical Devices - The Hubei Pathology Big Data Database has become the second-largest globally, with 170,000 high-precision digital slices, expected to exceed 500,000 by the end of 2025 [8]. - China leads the world in medical device patent applications, accounting for nearly 70% of the global total, showcasing its strong research output in this field [8]. Group 4: Agricultural Biotechnology - The agricultural biotechnology market in China accounts for 23% of the global market, with significant advancements in genetically modified crops [12]. - The application of synthetic biology and gene editing is driving growth in biomanufacturing, with a focus on biopharmaceuticals, biomaterials, and bioenergy [12]. Group 5: Future Outlook - The global biomanufacturing market is projected to grow significantly, with estimates suggesting a rise from $4-5 trillion to $30 trillion by 2050, indicating a compound annual growth rate of 8.6% [11]. - The integration of artificial intelligence in life sciences is expected to enhance drug development efficiency and expand applications across various sectors, including healthcare and agriculture [12].

Group 1 - China ranks second globally in the number of CAR-T clinical research centers, with 388 centers, reflecting a 60% increase from 2020 [2] - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with over 30% of new drug approvals and research pipelines globally [1][3] - The number of in-development drugs in China is second globally, with a narrowing gap compared to the United States [3] Group 2 - The establishment of 23 biomanufacturing bases across China indicates a robust growth trajectory in the biomanufacturing sector [1] - The "National Innovation Drug Insight System" aims to enhance the efficiency of innovative drug development by integrating data across the R&D and approval chain [4] - The biomanufacturing industry is projected to grow significantly, with the global bio-based chemicals market expected to reach $125.23 billion by 2029 [5][6] Group 3 - China leads globally in the number of medical device patent applications, accounting for nearly 70% of the total [3] - The biomanufacturing sector is expected to become a key driver of economic growth, with significant advancements in synthetic biology and gene editing technologies [7] - The agricultural biotechnology market in China is projected to reduce production costs and pesticide usage, with transgenic crops entering the industrial demonstration phase [6]

Group 1: Overview of China's Biomanufacturing Industry - The value added by the biomanufacturing sector accounts for over 7% of China's GDP [4] - China ranks second globally in the number of CAR-T cell therapy research centers and the number of biopharmaceuticals under research [1][4] - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with a significant number of innovative drugs and research pipelines [5] Group 2: Innovations and Developments - The "National Innovation Drug Insight System" was launched to enhance the efficiency of innovative drug development and address industry challenges [7] - The Hubei Pathology Big Database has reached 170,000 high-precision digital slices, positioning it as the second largest globally [6] - The global CAR-T clinical research centers have increased by 60% from 2020 to 2024, with China contributing 388 centers [5] Group 3: Market Growth and Future Projections - The global biomanufacturing market is projected to grow significantly, with the biobased chemicals market expected to reach $125.23 billion by 2029 [8] - China's biomanufacturing sector is positioned as a new engine for economic growth, supported by national policies and strategic planning [8] - The biotechnological innovations in agriculture, such as genetically modified crops, are set to enter the industrialization demonstration phase in 2024 [9]